Cargando…

Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey

PURPOSE: The aim of this study was to produce evidence on quality of life (QoL) among Italian growth hormone deficiency (GHD) children and adolescents treated with growth hormone (GH) and their parents. METHODS: A survey was conducted among Italian children and adolescents aged 4–18 with a confirmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Maghnie, M., Orso, M., Polistena, B., Cappa, M., Pozzobon, G., d’Angela, D., Patti, G., Spandonaro, F., Granato, S., Di Virgilio, R., La Torre, D., Salerno, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632207/
https://www.ncbi.nlm.nih.gov/pubmed/37209402
http://dx.doi.org/10.1007/s40618-023-02106-3
_version_ 1785146115777101824
author Maghnie, M.
Orso, M.
Polistena, B.
Cappa, M.
Pozzobon, G.
d’Angela, D.
Patti, G.
Spandonaro, F.
Granato, S.
Di Virgilio, R.
La Torre, D.
Salerno, M.
author_facet Maghnie, M.
Orso, M.
Polistena, B.
Cappa, M.
Pozzobon, G.
d’Angela, D.
Patti, G.
Spandonaro, F.
Granato, S.
Di Virgilio, R.
La Torre, D.
Salerno, M.
author_sort Maghnie, M.
collection PubMed
description PURPOSE: The aim of this study was to produce evidence on quality of life (QoL) among Italian growth hormone deficiency (GHD) children and adolescents treated with growth hormone (GH) and their parents. METHODS: A survey was conducted among Italian children and adolescents aged 4–18 with a confirmed diagnosis of GHD and treated with GH therapy and their parents. The European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L) and the Quality of Life in Short Stature Youth (QoLISSY) questionnaires were administered between May and October 2021 through the Computer-Assisted Personal Interview (CAPI) method. Results were compared with national and international reference values. RESULTS: The survey included 142 GHD children/adolescents and their parents. The mean EQ-5D-3L score was 0.95 [standard deviation (SD) 0.09], while the mean visual analogue scale (VAS) score was 86.2 (SD 14.2); the scores are similar to those of a reference Italian population aged 18–24 of healthy subjects. As for the QoLISSY child-version, compared to the international reference values for GHD/ idiopathic short stature (ISS) patients, we found a significantly higher score for the physical domain, and lower scores for coping and treatment; compared to the specific reference values for GHD patients, our mean scores were significantly lower for all domains except the physical one. As for the parents, we found a significantly higher score for the physical domain, and a lower score for treatment; compared to reference values GHD-specific, we found lower score in the social, emotional, treatment, parental effects, and total score domains. CONCLUSIONS: Our results suggest that the generic health-related quality of life (HRQoL) in treated GHD patients is high, comparable to that of healthy people. The QoL elicited by a disease specific questionnaire is also good, and comparable with that of international reference values of GHD/ISS patients.
format Online
Article
Text
id pubmed-10632207
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106322072023-11-14 Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey Maghnie, M. Orso, M. Polistena, B. Cappa, M. Pozzobon, G. d’Angela, D. Patti, G. Spandonaro, F. Granato, S. Di Virgilio, R. La Torre, D. Salerno, M. J Endocrinol Invest Original Article PURPOSE: The aim of this study was to produce evidence on quality of life (QoL) among Italian growth hormone deficiency (GHD) children and adolescents treated with growth hormone (GH) and their parents. METHODS: A survey was conducted among Italian children and adolescents aged 4–18 with a confirmed diagnosis of GHD and treated with GH therapy and their parents. The European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L) and the Quality of Life in Short Stature Youth (QoLISSY) questionnaires were administered between May and October 2021 through the Computer-Assisted Personal Interview (CAPI) method. Results were compared with national and international reference values. RESULTS: The survey included 142 GHD children/adolescents and their parents. The mean EQ-5D-3L score was 0.95 [standard deviation (SD) 0.09], while the mean visual analogue scale (VAS) score was 86.2 (SD 14.2); the scores are similar to those of a reference Italian population aged 18–24 of healthy subjects. As for the QoLISSY child-version, compared to the international reference values for GHD/ idiopathic short stature (ISS) patients, we found a significantly higher score for the physical domain, and lower scores for coping and treatment; compared to the specific reference values for GHD patients, our mean scores were significantly lower for all domains except the physical one. As for the parents, we found a significantly higher score for the physical domain, and a lower score for treatment; compared to reference values GHD-specific, we found lower score in the social, emotional, treatment, parental effects, and total score domains. CONCLUSIONS: Our results suggest that the generic health-related quality of life (HRQoL) in treated GHD patients is high, comparable to that of healthy people. The QoL elicited by a disease specific questionnaire is also good, and comparable with that of international reference values of GHD/ISS patients. Springer International Publishing 2023-05-20 2023 /pmc/articles/PMC10632207/ /pubmed/37209402 http://dx.doi.org/10.1007/s40618-023-02106-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Maghnie, M.
Orso, M.
Polistena, B.
Cappa, M.
Pozzobon, G.
d’Angela, D.
Patti, G.
Spandonaro, F.
Granato, S.
Di Virgilio, R.
La Torre, D.
Salerno, M.
Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey
title Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey
title_full Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey
title_fullStr Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey
title_full_unstemmed Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey
title_short Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey
title_sort quality of life in children and adolescents with growth hormone deficiency and their caregivers: an italian survey
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632207/
https://www.ncbi.nlm.nih.gov/pubmed/37209402
http://dx.doi.org/10.1007/s40618-023-02106-3
work_keys_str_mv AT maghniem qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT orsom qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT polistenab qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT cappam qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT pozzobong qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT dangelad qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT pattig qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT spandonarof qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT granatos qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT divirgilior qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT latorred qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey
AT salernom qualityoflifeinchildrenandadolescentswithgrowthhormonedeficiencyandtheircaregiversanitaliansurvey